235 related articles for article (PubMed ID: 34969858)
1. Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer.
Cordero A; Ramsey MD; Kanojia D; Fares J; Petrosyan E; Schwartz CW; Burga R; Zhang P; Rashidi A; Castro B; Xiao T; Lee-Chang C; Miska J; Balyasnikova IV; Ahmed AU; Lesniak MS
Proc Natl Acad Sci U S A; 2022 Jan; 119(1):. PubMed ID: 34969858
[TBL] [Abstract][Full Text] [Related]
2. Neural Stem Cells Secreting Anti-HER2 Antibody Improve Survival in a Preclinical Model of HER2 Overexpressing Breast Cancer Brain Metastases.
Kanojia D; Balyasnikova IV; Morshed RA; Frank RT; Yu D; Zhang L; Spencer DA; Kim JW; Han Y; Yu D; Ahmed AU; Aboody KS; Lesniak MS
Stem Cells; 2015 Oct; 33(10):2985-94. PubMed ID: 26260958
[TBL] [Abstract][Full Text] [Related]
3. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Murthy RK; Loi S; Okines A; Paplomata E; Hamilton E; Hurvitz SA; Lin NU; Borges V; Abramson V; Anders C; Bedard PL; Oliveira M; Jakobsen E; Bachelot T; Shachar SS; Müller V; Braga S; Duhoux FP; Greil R; Cameron D; Carey LA; Curigliano G; Gelmon K; Hortobagyi G; Krop I; Loibl S; Pegram M; Slamon D; Palanca-Wessels MC; Walker L; Feng W; Winer EP
N Engl J Med; 2020 Feb; 382(7):597-609. PubMed ID: 31825569
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis.
DeBusk K; Abeysinghe S; Vickers A; Nangia A; Bell J; Ike C; Forero-Torres A; Blahna MT
Future Oncol; 2021 Nov; 17(33):4635-4647. PubMed ID: 34463120
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models.
Kulukian A; Lee P; Taylor J; Rosler R; de Vries P; Watson D; Forero-Torres A; Peterson S
Mol Cancer Ther; 2020 Apr; 19(4):976-987. PubMed ID: 32241871
[TBL] [Abstract][Full Text] [Related]
6. Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer-Targeted Therapies.
O'Brien NA; Huang HKT; McDermott MSJ; Madrid AM; Luo T; Ayala R; Issakhanian S; Gong KW; Lu M; Zhang J; Slamon DJ
Mol Cancer Ther; 2022 May; 21(5):751-761. PubMed ID: 35417017
[TBL] [Abstract][Full Text] [Related]
7. Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).
Mueller V; Wardley A; Paplomata E; Hamilton E; Zelnak A; Fehrenbacher L; Jakobsen E; Curtit E; Boyle F; Harder Brix E; Brenner A; Crouzet L; Ferrario C; Muñoz-Mateu M; Arkenau HT; Iqbal N; Aithal S; Block M; Cold S; Cancel M; Hahn O; Poosarla T; Stringer-Reasor E; Colleoni M; Cameron D; Curigliano G; Siadak M; DeBusk K; Ramos J; Feng W; Gelmon K
Eur J Cancer; 2021 Aug; 153():223-233. PubMed ID: 34214937
[TBL] [Abstract][Full Text] [Related]
8. Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases.
Kodack DP; Chung E; Yamashita H; Incio J; Duyverman AM; Song Y; Farrar CT; Huang Y; Ager E; Kamoun W; Goel S; Snuderl M; Lussiez A; Hiddingh L; Mahmood S; Tannous BA; Eichler AF; Fukumura D; Engelman JA; Jain RK
Proc Natl Acad Sci U S A; 2012 Nov; 109(45):E3119-27. PubMed ID: 23071298
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases.
Metzger Filho O; Leone JP; Li T; Tan-Wasielewski Z; Trippa L; Barry WT; Younger J; Lawler E; Walker L; Freedman RA; Tolaney SM; Krop I; Winer EP; Lin NU
Ann Oncol; 2020 Sep; 31(9):1231-1239. PubMed ID: 32461105
[TBL] [Abstract][Full Text] [Related]
10. Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies.
Frank RT; Edmiston M; Kendall SE; Najbauer J; Cheung CW; Kassa T; Metz MZ; Kim SU; Glackin CA; Wu AM; Yazaki PJ; Aboody KS
PLoS One; 2009 Dec; 4(12):e8314. PubMed ID: 20016813
[TBL] [Abstract][Full Text] [Related]
11. Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
Tesch ME; Gelmon KA
Drugs; 2020 Nov; 80(17):1811-1830. PubMed ID: 33021725
[TBL] [Abstract][Full Text] [Related]
12. Tucatinib: First Approval.
Lee A
Drugs; 2020 Jul; 80(10):1033-1038. PubMed ID: 32548668
[TBL] [Abstract][Full Text] [Related]
13. Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.
Borges VF; Ferrario C; Aucoin N; Falkson C; Khan Q; Krop I; Welch S; Conlin A; Chaves J; Bedard PL; Chamberlain M; Gray T; Vo A; Hamilton E
JAMA Oncol; 2018 Sep; 4(9):1214-1220. PubMed ID: 29955792
[TBL] [Abstract][Full Text] [Related]
14. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
Yao E; Zhou W; Lee-Hoeflich ST; Truong T; Haverty PM; Eastham-Anderson J; Lewin-Koh N; Gunter B; Belvin M; Murray LJ; Friedman LS; Sliwkowski MX; Hoeflich KP
Clin Cancer Res; 2009 Jun; 15(12):4147-56. PubMed ID: 19509167
[TBL] [Abstract][Full Text] [Related]
15. HER2-positive metastatic breast cancer: a comprehensive review.
Exman P; Tolaney SM
Clin Adv Hematol Oncol; 2021 Jan; 19(1):40-50. PubMed ID: 33493147
[TBL] [Abstract][Full Text] [Related]
16. Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies.
Mounsey LA; Deal AM; Keith KC; Benbow JM; Shachar SS; Zagar T; Dees EC; Carey LA; Ewend MG; Anders CK
Clin Breast Cancer; 2018 Feb; 18(1):29-37. PubMed ID: 28867445
[TBL] [Abstract][Full Text] [Related]
17. Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors.
Floros KV; Jacob S; Kurupi R; Fairchild CK; Hu B; Puchalapalli M; E Koblinski J; Dozmorov MG; Boikos SA; Scaltriti M; Faber AC
Cell Death Dis; 2021 Feb; 12(2):179. PubMed ID: 33589591
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis.
Lewis Phillips GD; Nishimura MC; Lacap JA; Kharbanda S; Mai E; Tien J; Malesky K; Williams SP; Marik J; Phillips HS
Breast Cancer Res Treat; 2017 Aug; 164(3):581-591. PubMed ID: 28493046
[TBL] [Abstract][Full Text] [Related]
19. Successful intracranial delivery of trastuzumab by gene-therapy for treatment of HER2-positive breast cancer brain metastases.
Zafir-Lavie I; Sherbo S; Goltsman H; Badinter F; Yeini E; Ofek P; Miari R; Tal O; Liran A; Shatil T; Krispel S; Shapir N; Neil GA; Benhar I; Panet A; Satchi-Fainaro R
J Control Release; 2018 Dec; 291():80-89. PubMed ID: 30342077
[TBL] [Abstract][Full Text] [Related]
20. HER2 Tyrosine Kinase Inhibitors in the Sensitization to Cancers Resistant to HER2 Antibodies.
Singla H; Munshi A
Crit Rev Oncog; 2020; 25(3):241-250. PubMed ID: 33463944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]